Anzeige
Mehr »
Lynx Broker
Login
Montag, 21.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 ISIN: US92532F1003 Ticker-Symbol: VX1 
Tradegate
21.10.19
20:55 Uhr
164,00 Euro
+6,08
+3,85 %
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
160,00
170,00
22:16
164,84
164,84
21:30

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
VERTEX PHARMACEUTICALS Aktien ab 5,00 US-Dollar handeln - Ohne versteckte Kosten!
22:10UPDATE 1-FDA approves Vertex Pharma's combo treatment for cystic fibrosis5
22:05VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report-
21:35The FDA sets a regulatory speed record, providing a snap OK for Vertex's breakthrough triplet for cystic fibrosis5
21:34FDA approves Vertex Pharma's combo treatment for cystic fibrosis7
21:10Vertex Pharma +4.1% on Trikafta approval12
19:46Reimbursement set in Spain for Vertex Pharma CF meds5
SoVertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia1.415Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and...
► Artikel lesen
FrVertex Receives European CHMP Positive Opinion for KALYDECO (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age293- If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - Vertex Pharmaceuticals (Europe) Limited today announces that...
► Artikel lesen
08.10.3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year31
02.10.Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock67
01.10.Vertex bolsters C-suite with new CMO, chief regulatory officer7
01.10.Vertex taps a team player to take over as CMO during a big transition at the top1
30.09.Vertex continues shopping, spending $20M upfront to access Ribometrix's RNA-drugging platform8
27.09.3 Big Stock Charts for Friday: Conagra Brands, HollyFrontier and Vertex Pharmaceuticals10
24.09.Vertex Pharmaceuticals: zusätzliches Potenzial rückt ins Blickfeld!479New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Analyst Michael Yee von Jefferies & Co: Michael Yee, Aktienanalyst von Jefferies & Co, spricht für die Aktien des US-Biotechkonzerns...
► Artikel lesen
18.09.LIVING CELL TECHNOLOGIES LIMITED: LCT to benefit from Semma Therapeutics acquisition by Vertex17
17.09.VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report4
16.09.Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland8
13.09.Vertex deal for Scotland - no deal for England10
13.09.Vertex scores CF deal with Scotland, but access debate continues4
Seite:  Weiter >>
140 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,1,4